Verdence Capital Advisors LLC grew its holdings in Boston Scientific Co. (NYSE:BSX – Free Report) by 4.3% in the 3rd quarter, ...

"Tivic hits enrolment target for vagus nerve stimulation trial" was originally created and published by Medical Device ...

Boston Scientific Corporation develops, manufactures ... and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

Boston Scientific disclaims any intention or obligation ... digits organically and double-digits operationally. Our global SCS performance was below our expectations in a market that continues ...

Erica Denhoff / Icon Sportswire via Getty Images Boston Scientific shares fell Wednesday as its third-quarter profit missed estimates. The medical device maker's adjusted earnings per share and ...

Credit: Sundry Photography via Shutterstock. Boston Scientific has resumed enrolment for its AVANT GUARD clinical trial, after it was paused in October 2024to “assess a few unanticipated observations” ...

Marlborough-based Boston Scientific increased its estimated net sales growth for 2024. Meanwhile, Thermo Fisher slightly raised its full-year adjusted earnings per share guidance. Boston ...

Boston Scientific (NYSE: BSX) + today reported third-quarter results that came in ahead of the consensus forecast, raising its 2024 guidance again. The company’s CEO also said on its third ...